Off-The-Shelf Immunotherapy Product Induces Positive Response in Patients with NHL
December 7, 2019
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
SUBSCRIBE: Print / eNewsletter
Mosunetuzumab generated durable responses in patients with highly refractory non-Hodgkin lymphomas.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
